FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

9 letters match. Newest first.

  1. NexCell Scientific Inc

    NexCell Scientific markets an unapproved, unlicensed umbilical cord blood cell product with serious manufacturing violations.

    High risk
  2. Jabil Inc.

    FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

    High risk
  3. Excelvision - Fareva

    FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.

    High risk
  4. Huons Co., Ltd.

    FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.

    High risk
  5. Pharmathen International S.A.

    FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.

    High risk
  6. UCSF Radiopharmaceutical Facility

    FDA cited UCSF Radiopharmaceutical Facility for inadequate sterility failure investigations and environmental monitoring of sterile drug manufacturing.

    High risk
  7. Boothwyn Pharmacy, LLC

    Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.

    High risk
  8. Oasis Medical, Inc.

    FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.

    High risk
  9. Apothecary Health Solutions/Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop

    FDA cited Carie Boyd's Prescription Shop for compounded drugs that failed outsourcing-facility labeling and reporting rules.

    Medium